DarioHealth Corp. (NASDAQ:DRIO - Get Free Report) Director Dennis Matheis purchased 14,430 shares of the stock in a transaction that occurred on Thursday, July 23rd. The stock was bought at an average cost of $6.93 per share, with a total value of $99,999.90. Following the acquisition, the director owned 43,026 shares of the company's stock, valued at $298,170.18. This represents a 50.46% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.
DarioHealth Stock Performance
DRIO stock opened at $7.49 on Wednesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.07 and a quick ratio of 2.62. The company has a 50 day moving average price of $7.18 and a 200 day moving average price of $8.64. DarioHealth Corp. has a fifty-two week low of $5.84 and a fifty-two week high of $17.74. The stock has a market capitalization of $54.99 million, a PE ratio of -0.84 and a beta of 1.09.
Hedge Funds Weigh In On DarioHealth
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Kestra Advisory Services LLC acquired a new stake in DarioHealth during the 4th quarter worth $35,000. XTX Topco Ltd lifted its stake in shares of DarioHealth by 229.0% in the 2nd quarter. XTX Topco Ltd now owns 62,511 shares of the company's stock valued at $42,000 after purchasing an additional 43,513 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of DarioHealth by 167.9% in the 4th quarter. Geode Capital Management LLC now owns 49,567 shares of the company's stock valued at $564,000 after purchasing an additional 31,063 shares during the period. 33.39% of the stock is owned by institutional investors.
Analysts Set New Price Targets
DRIO has been the subject of a number of recent research reports. Weiss Ratings restated a "sell (e+)" rating on shares of DarioHealth in a research report on Friday, July 10th. TD Cowen reiterated a "hold" rating and issued a $11.00 price target on shares of DarioHealth in a report on Wednesday, May 13th. Finally, Stifel Nicolaus reiterated a "buy" rating and issued a $10.00 price objective on shares of DarioHealth in a research report on Thursday, May 14th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $10.50.
Check Out Our Latest Research Report on DarioHealth
DarioHealth Company Profile
(
Get Free Report)
DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.
The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
